530549 Stock Overview
Shilpa Medicare Limited, together with its subsidiaries, engages in the manufacturing and selling active pharmaceutical ingredients (APIs), intermediates, and formulations in India, the United States, Europe, and internationally.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Shilpa Medicare Limited Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₹461.35 |
52 Week High | ₹468.65 |
52 Week Low | ₹225.05 |
Beta | 0.78 |
1 Month Change | 7.05% |
3 Month Change | 39.63% |
1 Year Change | 101.99% |
3 Year Change | 30.14% |
5 Year Change | 38.23% |
Change since IPO | 20,253.68% |
Recent News & Updates
Recent updates
Shareholder Returns
530549 | IN Pharmaceuticals | IN Market | |
---|---|---|---|
7D | 1.2% | 2.4% | 1.8% |
1Y | 102.0% | 65.8% | 48.6% |
Return vs Industry: 530549 exceeded the Indian Pharmaceuticals industry which returned 63.9% over the past year.
Return vs Market: 530549 exceeded the Indian Market which returned 47.3% over the past year.
Price Volatility
530549 volatility | |
---|---|
530549 Average Weekly Movement | 7.9% |
Pharmaceuticals Industry Average Movement | 5.9% |
Market Average Movement | 6.6% |
10% most volatile stocks in IN Market | 10.1% |
10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 530549's share price has been volatile over the past 3 months.
Volatility Over Time: 530549's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1987 | 1,179 | Vishnukanth Bhutada | https://www.vbshilpa.com |
Shilpa Medicare Limited, together with its subsidiaries, engages in the manufacturing and selling active pharmaceutical ingredients (APIs), intermediates, and formulations in India, the United States, Europe, and internationally. It’s primary oncology and non-oncology APIs include capecitabine, gemcitabine hydrochloride, pemetrexed, axitinib, erlotinib hydrochloride, and irinotecan hydrochloride, as well as ambroxol, tranexmic acid, and ursodeoxycholic acid; and new drug delivery systems, peptides/biotech products, and specialty chemicals, etc. The company provides contract manufacturing of various dosage forms, such as tablets, capsules, liquid injections, lyophilized injectables, and sterile dry powder injectables. In addition, It is involved in the wind power generation activities.
Shilpa Medicare Limited Fundamentals Summary
530549 fundamental statistics | |
---|---|
Market cap | ₹40.05b |
Earnings (TTM) | -₹6.71m |
Revenue (TTM) | ₹11.25b |
3.6x
P/S Ratio-5,971x
P/E RatioIs 530549 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
530549 income statement (TTM) | |
---|---|
Revenue | ₹11.25b |
Cost of Revenue | ₹4.44b |
Gross Profit | ₹6.81b |
Other Expenses | ₹6.81b |
Earnings | -₹6.71m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.077 |
Gross Margin | 60.53% |
Net Profit Margin | -0.06% |
Debt/Equity Ratio | 48.8% |
How did 530549 perform over the long term?
See historical performance and comparison